Cargando…

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age

PURPOSE: Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have not been explored. PATIENTS AND METHODS: We prospectively registered AA...

Descripción completa

Detalles Bibliográficos
Autores principales: Rank, Cecilie U., Wolthers, Benjamin O., Grell, Kathrine, Albertsen, Birgitte K., Frandsen, Thomas L., Overgaard, Ulrik M., Toft, Nina, Nielsen, Ove J., Wehner, Peder S., Harila-Saari, Arja, Heyman, Mats M., Malmros, Johan, Abrahamsson, Jonas, Norén-Nyström, Ulrika, Tomaszewska-Toporska, Beata, Lund, Bendik, Jarvis, Kirsten B., Quist-Paulsen, Petter, Vaitkevičienė, Goda E., Griškevičius, Laimonas, Taskinen, Mervi, Wartiovaara-Kautto, Ulla, Lepik, Kristi, Punab, Mari, Jónsson, Ólafur G., Schmiegelow, Kjeld
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953441/
https://www.ncbi.nlm.nih.gov/pubmed/31770057
http://dx.doi.org/10.1200/JCO.19.02208
_version_ 1783486624163692544
author Rank, Cecilie U.
Wolthers, Benjamin O.
Grell, Kathrine
Albertsen, Birgitte K.
Frandsen, Thomas L.
Overgaard, Ulrik M.
Toft, Nina
Nielsen, Ove J.
Wehner, Peder S.
Harila-Saari, Arja
Heyman, Mats M.
Malmros, Johan
Abrahamsson, Jonas
Norén-Nyström, Ulrika
Tomaszewska-Toporska, Beata
Lund, Bendik
Jarvis, Kirsten B.
Quist-Paulsen, Petter
Vaitkevičienė, Goda E.
Griškevičius, Laimonas
Taskinen, Mervi
Wartiovaara-Kautto, Ulla
Lepik, Kristi
Punab, Mari
Jónsson, Ólafur G.
Schmiegelow, Kjeld
author_facet Rank, Cecilie U.
Wolthers, Benjamin O.
Grell, Kathrine
Albertsen, Birgitte K.
Frandsen, Thomas L.
Overgaard, Ulrik M.
Toft, Nina
Nielsen, Ove J.
Wehner, Peder S.
Harila-Saari, Arja
Heyman, Mats M.
Malmros, Johan
Abrahamsson, Jonas
Norén-Nyström, Ulrika
Tomaszewska-Toporska, Beata
Lund, Bendik
Jarvis, Kirsten B.
Quist-Paulsen, Petter
Vaitkevičienė, Goda E.
Griškevičius, Laimonas
Taskinen, Mervi
Wartiovaara-Kautto, Ulla
Lepik, Kristi
Punab, Mari
Jónsson, Ólafur G.
Schmiegelow, Kjeld
author_sort Rank, Cecilie U.
collection PubMed
description PURPOSE: Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have not been explored. PATIENTS AND METHODS: We prospectively registered AAP (n = 168) during treatment of 2,448 consecutive ALL patients aged 1.0-45.9 years diagnosed from July 2008 to October 2018 and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol. RESULTS: Compared with patients aged 1.0-9.9 years, adjusted AAP hazard ratios (HRa) were associated with higher age with almost identical HRa (1.6; 95% CI, 1.1 to 2.3; P = .02) for adolescents (10.0-17.9 years) and adults (18.0-45.9 years). The day 280 cumulative incidences of AAP were 7.0% for children (1.0-9.9 years: 95% CI, 5.4 to 8.6), 10.1% for adolescents (10.0 to 17.9 years: 95% CI, 7.0 to 13.3), and 11.0% for adults (18.0-45.9 years: 95% CI, 7.1 to 14.9; P = .03). Adolescents had increased odds of both acute (odds ratio [OR], 5.2; 95% CI, 2.1 to 13.2; P = .0005) and persisting complications (OR, 6.7; 95% CI, 2.4 to 18.4; P = .0002) compared with children (1.0-9.9 years), whereas adults had increased odds of only persisting complications (OR, 4.1; 95% CI, 1.4 to 11.8; P = .01). Fifteen of 34 asparaginase-rechallenged patients developed a second AAP. Asparaginase was truncated in 17/21 patients with AAP who subsequently developed leukemic relapse, but neither AAP nor the asparaginase truncation was associated with increased risk of relapse. CONCLUSION: Older children and adults had similar AAP risk, whereas morbidity was most pronounced among adolescents. Asparaginase re-exposure should be considered only for patients with an anticipated high risk of leukemic relapse, because multiple studies strongly indicate that reduction of asparaginase treatment intensity increases the risk of relapse.
format Online
Article
Text
id pubmed-6953441
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-69534412021-01-10 Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age Rank, Cecilie U. Wolthers, Benjamin O. Grell, Kathrine Albertsen, Birgitte K. Frandsen, Thomas L. Overgaard, Ulrik M. Toft, Nina Nielsen, Ove J. Wehner, Peder S. Harila-Saari, Arja Heyman, Mats M. Malmros, Johan Abrahamsson, Jonas Norén-Nyström, Ulrika Tomaszewska-Toporska, Beata Lund, Bendik Jarvis, Kirsten B. Quist-Paulsen, Petter Vaitkevičienė, Goda E. Griškevičius, Laimonas Taskinen, Mervi Wartiovaara-Kautto, Ulla Lepik, Kristi Punab, Mari Jónsson, Ólafur G. Schmiegelow, Kjeld J Clin Oncol ORIGINAL REPORTS PURPOSE: Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have not been explored. PATIENTS AND METHODS: We prospectively registered AAP (n = 168) during treatment of 2,448 consecutive ALL patients aged 1.0-45.9 years diagnosed from July 2008 to October 2018 and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol. RESULTS: Compared with patients aged 1.0-9.9 years, adjusted AAP hazard ratios (HRa) were associated with higher age with almost identical HRa (1.6; 95% CI, 1.1 to 2.3; P = .02) for adolescents (10.0-17.9 years) and adults (18.0-45.9 years). The day 280 cumulative incidences of AAP were 7.0% for children (1.0-9.9 years: 95% CI, 5.4 to 8.6), 10.1% for adolescents (10.0 to 17.9 years: 95% CI, 7.0 to 13.3), and 11.0% for adults (18.0-45.9 years: 95% CI, 7.1 to 14.9; P = .03). Adolescents had increased odds of both acute (odds ratio [OR], 5.2; 95% CI, 2.1 to 13.2; P = .0005) and persisting complications (OR, 6.7; 95% CI, 2.4 to 18.4; P = .0002) compared with children (1.0-9.9 years), whereas adults had increased odds of only persisting complications (OR, 4.1; 95% CI, 1.4 to 11.8; P = .01). Fifteen of 34 asparaginase-rechallenged patients developed a second AAP. Asparaginase was truncated in 17/21 patients with AAP who subsequently developed leukemic relapse, but neither AAP nor the asparaginase truncation was associated with increased risk of relapse. CONCLUSION: Older children and adults had similar AAP risk, whereas morbidity was most pronounced among adolescents. Asparaginase re-exposure should be considered only for patients with an anticipated high risk of leukemic relapse, because multiple studies strongly indicate that reduction of asparaginase treatment intensity increases the risk of relapse. American Society of Clinical Oncology 2020-01-10 2019-11-26 /pmc/articles/PMC6953441/ /pubmed/31770057 http://dx.doi.org/10.1200/JCO.19.02208 Text en © 2019 by American Society of Clinical Oncology http://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle ORIGINAL REPORTS
Rank, Cecilie U.
Wolthers, Benjamin O.
Grell, Kathrine
Albertsen, Birgitte K.
Frandsen, Thomas L.
Overgaard, Ulrik M.
Toft, Nina
Nielsen, Ove J.
Wehner, Peder S.
Harila-Saari, Arja
Heyman, Mats M.
Malmros, Johan
Abrahamsson, Jonas
Norén-Nyström, Ulrika
Tomaszewska-Toporska, Beata
Lund, Bendik
Jarvis, Kirsten B.
Quist-Paulsen, Petter
Vaitkevičienė, Goda E.
Griškevičius, Laimonas
Taskinen, Mervi
Wartiovaara-Kautto, Ulla
Lepik, Kristi
Punab, Mari
Jónsson, Ólafur G.
Schmiegelow, Kjeld
Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age
title Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age
title_full Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age
title_fullStr Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age
title_full_unstemmed Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age
title_short Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age
title_sort asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the nopho all2008 treatment of patients 1-45 years of age
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953441/
https://www.ncbi.nlm.nih.gov/pubmed/31770057
http://dx.doi.org/10.1200/JCO.19.02208
work_keys_str_mv AT rankcecilieu asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT wolthersbenjamino asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT grellkathrine asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT albertsenbirgittek asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT frandsenthomasl asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT overgaardulrikm asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT toftnina asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT nielsenovej asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT wehnerpeders asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT harilasaariarja asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT heymanmatsm asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT malmrosjohan asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT abrahamssonjonas asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT norennystromulrika asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT tomaszewskatoporskabeata asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT lundbendik asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT jarviskirstenb asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT quistpaulsenpetter asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT vaitkevicienegodae asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT griskeviciuslaimonas asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT taskinenmervi asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT wartiovaarakauttoulla asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT lepikkristi asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT punabmari asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT jonssonolafurg asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage
AT schmiegelowkjeld asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage